Vitality Watch

Dossier pubmed review 06-jul-2026
Narrative review or expert overview without new data

Aging of mesenchymal stem cells in bone aging: Mechanisms, impact, and therapeutic perspectives.

Key claim: Senescence of bone marrow mesenchymal stem cells—via impaired proliferation and osteogenic differentiation, epigenetic dysregulation, and a pro-inflammatory SASP—drives age-related bone loss, with senolytics, metabolic modulators, and extracellular-vesicle approaches proposed as therapeutic paths.

Abstract

Aging of the skeleton is a hallmark of organismal decline and underlies prevalent age-related disorders such as osteoporosis and osteoarthritis. Bone marrow-derived mesenchymal stem cells (BMSCs), the primary source of osteoblasts, undergo profound functional deterioration during senescence, leading to an imbalance between bone formation and resorption. This review systematically summarizes the key features of BMSC senescence, including impaired proliferation and differentiation, epigenetic dysregulation, and the acquisition of a pro-inflammatory senescence-associated secretory phenotype (SASP). We highlight recent advances in understanding how epigenetic mechanisms (DNA methylation, histone modifications, RNA methylation, and non-coding RNAs) orchestrate BMSC aging. In addition, we discuss the intricate crosstalk between senescent BMSCs and the bone microenvironment, emphasizing their contribution to age-related bone diseases. Finally, we propose future research directions, including the integration of multi‑omics, single-cell technologies, and targeted epigenetic interventions, as well as emerging therapeutic strategies such as senolytics, metabolic modulators, and extracellular vesicle-based approaches. A deeper understanding of BMSC aging will facilitate the development of novel treatments to preserve bone health and combat aging-related skeletal disorders.

Why this matters

Senescence of bone marrow mesenchymal stem cells—via impaired proliferation and osteogenic differentiation, epigenetic dysregulation, and a pro-inflammatory SASP—drives age-related bone loss, with senolytics, metabolic modulators, and extracellular-vesicle approaches proposed as therapeutic paths.

Source

Link

Briefing card

Aging of mesenchymal stem cells in bone aging: Mechanisms, impact, and therapeutic perspectives.
Stage: review · pubmed · 06-jul-2026

Senescence of bone marrow mesenchymal stem cells—via impaired proliferation and osteogenic differentiation, epigenetic dysregulation, and a pro-inflammatory SASP—drives age-related bone loss, with senolytics, metabolic modulators, and extracellular-vesicle approaches proposed as therapeutic paths.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.arr.2026.103240

build build 880 · 2bcef25 · 2026-11-18